Our goal is to improve the lives of patients from early childhood through adulthood by leveraging our pharmaceutical and clinical development expertise to develop pediatric friendly therapeutics that answer critical unmet medical needs in the field of rare and neglected diseases.
Distal Renal Tubular Acidosis, is a disease affecting the distal tubule of the kidney. It is an orphan disease which can be either genetic in origin or acquired. Nowadays, there is no treatment approved for dRTA. Watch the video for more information.
Our most advanced product is ADV7103, an innovative combination product, is being developed for the treatment of distal Renal Tubular Acidosis (dRTA), an orphan nephrology indication.
Keep updated with pharma specialty company Advicenne’s latest press releases.
Advicenne is a pharma specialty company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications.
Our goal is to improve the lives of patients from early childhood through adulthood by answering critical unmet needs in the field of orphan nephrology.